Intensity Therapeutics, Inc.’s Research Selected for Presentation at the 2015 American Association for Cancer Research Annual Meeting

WESTPORT, Conn.--(BUSINESS WIRE)-- Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary immune-based cancer therapy products, announced that preclinical data using the Company's novel drug product, INT230-6, was selected for presentation at the 2015 American Association for Cancer Research (AACR) Annual Meeting. The conference is being held April 18 to 22, 2015 in the Pennsylvania Convention Center in Philadelphia, PA.

The research will be presented in a poster session and is co-authored by Ian B. Walters, MD, Chief Medical Officer, Lewis H. Bender, President & CEO of Intensity Therapeutics, Jay A. Berzofsky, MD, PhD, Chief of the Vaccine Branch at the National Cancer Institute and Masaki Terabe, PhD, Associate Scientist also at the NCI’s Vaccine Branch. The research will also be published in the 2015 Proceedings of the American Association for Cancer Research.

The poster’s title is: INT230-6, a Novel Intratumoral Anticancer Agent, is able to Eradicate Large, Established Tumors and Stimulate Potent Antitumor Immunity.

Detailed information about viewing the poster presentation is:

About INT230-6

INT230-6 is a novel drug product formulation able to diffuse into cancer cells. Using in vivo preclinical models of severe cancer, INT230-6 treatment results in substantial improvement in survival with large tumors in some animals being completely cleared. Complete responders appear to be protected long term from recurrence of cancer. INT230-6 administration has shown an increased recruitment of immune cells to the tumor.

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a biotechnology company whose mission is to greatly extend the lives of patients with cancer. Intensity Therapeutics is pioneering a new immunotherapy approach to treat cancer using the Company’s DfuseRx^SM platform technology. The Company’s novel products when injected directly into tumors result in tumor regression from baseline and significantly increased survival. The technology attenuates (kills) a tumor in a manner that allows for the adaptive immune system to recognize the cancer to attack untreated tumors and prevent disease recurrence. Further information can be found at www.intensitytherapeutics.com

Forward-Looking Statements

This press release contains forward-looking statements regarding Intensity Therapeutics’ plans, future operations and objectives. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual performance or achievements to be materially different from those currently anticipated.  Forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.

Media & Investors:
Intensity Therapeutics, Inc.
Lewis Bender
President & CEO
8 Wright Street, Suite 107
Westport, CT 06880
Tel. (203) 682-2434
Email: lbender@intensitytherapeutics.com

Source: Intensity Therapeutics, Inc.

Released April 16, 2015